IP Library Granted Patent US 6,958,160
Granted Patent B1
US 6,958,160 · App. 10/262,284 · Granted Oct 25, 2005

Self forming, thermodynamically stable liposomes and their applications

Assignee: BioZone Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,958,160
App. No.
10/262,284
Granted
Oct 25, 2005
Kind
B1
Abstract

A liposome suspension forms spontaneously upon adding a lipid composition to an aqueous solution. The liposomes include diacylglycerol-PEG compounds. The melting point of the diacylglycerol-PEG is below about 40 degrees C., and the acyl chains of the diacylglycerol-PEG are greater than or equal to 14 carbons in length. Such liposome suspensions are useful for a variety of purposes, including the delivery of therapeutic agents.

Claims (17)

1. A liposome comprising:

one or more lipids where the total lipids have a P a between about 0.84 and 0.88 and a P v between about 0.88 and 0.93,

where P a is the packing parameter with respect to surface and P v is the packing parameter with respect to volume,

where one or more of the lipids is a diacylglycerol-PEG,

where the melting point of the diacylglycerol-PEG is below about 40 degrees C., and

where the acyl chains of the diacylglycerol-PEG are greater than or equal to 14 carbons in length.

2. The liposome of claim 1 , where the PEG chain of the diacylglycerol-PEG has a molecular weight between about 300 Daltons and 5000 Daltons.

3. The liposome of claim 1 , where the diacylglycerol-PEG comprises dioleolylglycerol-PEG-12.

4. The liposome of claim 1 , further comprising an active compound.

5. The liposome of claim 4 , where the active compound is selected from the group consisting of proteins, peptides, nucleic acids, agents for treating neoplasms, agents for treating inflammation, agents for treating infections, agents for treating gasterointestinal diseases, agents for treating immunological diseases, agents for treating skin diseases eye diseases, agents uses in diagnosing disease, nutrients, agents for treating blood diseases, agents for treating metabolic diseases, agents for treating cardiovascular diseases, agents for treating renal diseases, agents for treating genitourinary diseases, agents for treating respiratory diseases, and agents for treating central nervous system diseases.

6. The product of a process consisting essentially of:

providing one or more lipids where the total lipids have a P a between about 0.84 and 0.88 and a P v between about 0.88 and 0.93, where P a is the packing parameter with respect to surface and P v is the packing parameter with respect to volume and where one or more of the lipids is a diacylglycerol-PEG having a melting point below about 40 degrees C. and also having acyl chains greater than or equal to 14 carbons in length, and

combining the lipid or lipids with an aqueous solution at a temperature above the melting point of the lipid or lipids.

7. The product of claim 6 , where the PEG chain of the diacylglycerol-PEG has a molecular weight between about 300 Daltons and 5000 Daltons.

8. The product of claim 6 , where the diacylglycerol-PEG comprises dioleolylglycerol-PEG-12.

9. The product of claim 6 , further comprising an active compound.

10. The product of claim 9 , where the active compound is selected from the group consisting of proteins, peptides, nucleic acids, agents for treating neoplasms, agents for treating inflammation, agents for treating infections, agents for treating gasterointestinal diseases, agents for treating immunological diseases, agents for treating skin diseases eye diseases, agents uses in diagnosing disease, nutrients, agents for treating blood diseases, agents for treating metabolic diseases, agents for treating cardiovascular diseases, agents for treating renal diseases, agents for treating genitourinary diseases, agents for treating respiratory diseases, and agents for treating central nervous system diseases.

Assignments (8)
RELEASE Recorded Dec 20, 2017
From: BMO HARRIS BANK N.A., AS AGENT
To: BIOZONE LABORATORIES INC.
Reel/Frame 044919/0700 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Oct 18, 2016
From: WELLS FARGO BANK, N.A., AS AGENT
To: BIOZONE LABORATORIES INC.
Reel/Frame 040387/0645 →
SECURITY AGREEMENT Recorded Oct 6, 2016
From: BIOZONE LABORATORIES INC.
To: BMO HARRIS BANK N.A., AS AGENT
Reel/Frame 040249/0056 →
SECURITY INTEREST Recorded May 18, 2016
From: BIOZONE LABORATORIES INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 038638/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2016
From: EQUACHEM, LLC.
To: BIOZONE LABORATORIES, INC.
Reel/Frame 038515/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2008
From: BRIAN CHARLES KELLAR OF BIOZONE LABORATORIES, INC.
To: EQUACHEM, LLC
Reel/Frame 020845/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2005
From: LASIC, ALENKA
To: BIOZONE LABORATORIES, INC.
Reel/Frame 016335/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2005
From: KELLER, BRIAN CHARLES
To: BIOZONE LABORATORIES, INC.
Reel/Frame 015613/0261 →
Continuity (1)
Continuation 0974529200 · Dec 20, 2000